BCL2 and melanoma: Additionally, dual targeting with the Bcl-2 inhibitor, ABT-737, and the γ-secretase Inhibitor, GSI, revealed a high efficiency in reducing the cell viability, disrupting colony formation, decreasing ALDH+ cells, and inhibiting the self-renewal of melanoma CSCs [211], indicating that this combinational therapy might be another promising strategy to address treatment relapse of malignant melanoma.